Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) Meeting Abstract

  

Authors:	Campone, M.; Bardia, A.; Ulaner, G. A.; Chandarlapaty, S.; Gosselin, A.; Doroumian, S.; Pelekanou, V.; Celanovic, M.; Linden, H. M.
Abstract Title:	Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC)
Meeting Title:	56th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	38
Issue:	15 Suppl.
Meeting Dates:	2020 May 29-31
Meeting Location:	Virtual
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2020-05-20
Start Page:	48s
Language:	English
ACCESSION:	WOS:000560368300291
PROVIDER:	wos
DOI:	10.1200/JCO.2020.38.15_suppl.1070
Notes:	Meeting Abstract: 1070 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/172838